Vikrant Salaria, MD
Internal Medicine · Council Bluffs, IANPI 1043211493
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 412 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 412 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$934
- AstraZeneca$920
- Novo Nordisk$642
- Pfizer$598
- AbbVie$537
- Amgen$460
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,709100%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 64 | $934 |
| AstraZeneca | 51 | $920 |
| Novo Nordisk | 41 | $642 |
| Pfizer | 33 | $598 |
| AbbVie(2 entities) | 27 | $537 |
| Amgen | 30 | $460 |
| Johnson & Johnson | 19 | $296 |
| Novartis | 16 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $230 |
| Merck | 14 | $215 |
| Mylan Specialty L.p. | 11 | $173 |
| Bayer | 9 | $153 |
| Boehringer Ingelheim | 10 | $143 |
| Abbott | 7 | $138 |
| Antares Pharma, Inc. | 8 | $130 |
| Mallinckrodt Hospital Products Inc. | 6 | $126 |
| GSK | 9 | $125 |
| E.r. Squibb & Sons, L.L.C. | 8 | $109 |
| Philips North America LLC | 5 | $91 |
| Paratek Pharmaceuticals, Inc. | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Kowa Pharmaceuticals America, Inc. | 4 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Melinta Therapeutics, LLC | 2 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Optos, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
How this compares
$6,743 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $135,043 |
| MounjaroTirzepatide | 48 | $55,265 |
| JardianceEmpagliflozin | 46 | $48,037 |
| XareltoRivaroxaban | 36 | $46,688 |
| TrulicityDulaglutide | 42 | $45,628 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $40,524 |
| XifaxanRifaximin | 12 | $39,412 |
| FarxigaDapagliflozin Propanediol | 44 | $34,198 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $28,575 |
| EliquisApixaban | 26 | $28,336 |
| SynjardyEmpagliflozin/Metformin Hcl | 25 | $20,791 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $18,276 |
| KerendiaFinerenone | 21 | $17,474 |
| Nurtec OdtRimegepant Sulfate | 16 | $17,139 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $16,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $642 | $135,043118 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Combivent Respimat | $143 | $115,679118 claims |
| Lilly USA, LLCMounjaro, Trulicity | $934 | $100,89390 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Breo Ellipta | $125 | $60,74989 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $920 | $50,44865 claims |
| Johnson & JohnsonXarelto | $296 | $46,68836 claims |
| PfizerEliquis, Nurtec Odt | $598 | $45,47542 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $28 | $39,41212 claims |
| BayerKerendia | $153 | $17,47421 claims |
| AbbVieNamzaric | $537 | $12,90516 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $230 | $5,42211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Council Bluffs
- Alan KricsfeldCouncil Bluffs$49K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
- Barry KricsfeldCouncil Bluffs$13K
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Aziz HammoudIowa City$29K
- Ali SaeedCedar Rapids$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.